Pharmafile Logo
Pharmafocus logo
Advanced Search
headquarters_3_web

Eli Lilly Q1 earnings miss estimates, ups FY view; shares drop 2%

April 27, 2016
Research and Development, Sales and Marketing Eli Lilly, FY, Q1, earnings, revenue, sales

Shares in US drugmaker Eli Lilly (NYSE: LLY) dropped to close down over 2% Tuesday after the company posted first-quarter …

News
abpi_reception

ABPI welcomes recommendations from NHS specialised services report

April 27, 2016
Research and Development, Sales and Marketing ABPI, NHS, NHS England, NICE, National Audit Office, report, specialised services

The ABPI has welcomed the findings of a National Audit Office report on the commission of specialised service by NHS …

News
shirelabsus

Shire to close Hampshire base and relocate jobs, say reports

April 27, 2016
Manufacturing and Production, Research and Development Jobs, Shire, close, factory, hampshire, loss, relocate

Shire is set to cease operations at its site in Basingstoke, Hampshire, by the end of next year and relocate …

News
ironwood_pharma

AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals

April 27, 2016
Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales

AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …

News
novartis_outside_1

Novartis’ Ilaris gets US FDA breakthrough therapy designation to treat fever syndromes

April 27, 2016
Business Services, Research and Development Breakthrough Therapy Designation, Novartis, US FDA, periodic fever syndromes

Novartis (VTX: NOVN) on Wednesday said its drug to treat three rare types of periodic fever syndromes has been granted …

News
eli_lilly_logo

Eli Lilly gets European marketing authorisation for psoriasis drug

April 26, 2016
EC, EU, Eli Lilly, drug trial, psoriasis, regulation

US pharma firm Eli Lilly and Co (NYSE: LLY) on Tuesday said the European Commission backed marketing authorisation for its …

News
hawthorn_eisai

Eisai poaches senior Pfizer and Sanofi execs for neurology group

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim

Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …

Appointment
neil_lister_perrigo

Perrigo name new head of its combined UK and Ireland business

April 26, 2016
Sales and Marketing Ireland, Perrigo, UK, lister, neil, new head

Perrigo has named Neil Lister as the head of its newly-combined UK and Ireland business. The manufacturer and distributor of …

Appointment
george-freeman1

Northern Powerhouse life sciences contributing £10 billion to UK economy, says minister

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Jobs, Northern Powerhouse, contribution, economy, exporting, george freeman, investment, life sciences, minister, north

Minister for Life Sciences, George Freeman MP, has revealed that life sciences businesses within the Northern Powerhouse are contributing over …

News
clinicaltrial1

US panel says Sarepta’s trial DMD drug not proven effective

April 26, 2016
Manufacturing and Production, Research and Development DMD, US FDA, drug trial, sarepta

A US advisory committee has concluded Sarepta Therapeutics’ (Nasdaq: SRPT) trial drug to treat muscle wasting condition has not proved …

News
credit_bayerag

Bayer’s earnings beat estimates as blockbusters shine

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales

Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …

News
astrazeneca_building_white

AstraZeneca’s COPD therapy gets US FDA approval

April 26, 2016
Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval

UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …

News
allergan_waco

Allergan breaks ground on $200 million expansion at Texas site

April 26, 2016
Manufacturing and Production Allergan, doubling, expansion, eye care, facility, investment, manufacturing, size, texas, waco

Allergan (NYSE: AGN) has broken ground on a $200 million expansion at its manufacturing facility in Waco, Texas. The expansion …

News
novartis_mit_us

Novartis exploring almost $14-billion stake sale in Roche – reports

April 26, 2016
Manufacturing and Production, Sales and Marketing Financial, Merger & Acquisition, Novartis, Roche, Stake sale

Swiss pharma firm Novartis (VTX: NOVN) maybe looking at options to sell its one-third stake in cancer drugmaker Roche’s (VTX: …

News
gilead-sciences

EU grants approval for Gilead’s HIV treatment Descovy

April 26, 2016
Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf

Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …

News
joseph_papa

Valeant names Joseph Papa as new chief executive officer

April 25, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Chairman, Valeant, joseph papa, new, new ceo, papa, pearson

Valeant Pharmaceuticals has announced that Joseph C. Papa will succeed Michael Pearson as chairman and chief executive officer of the …

Appointment
test_results

FDA, WHO criticise integrity of data at contract research firm Semler

April 25, 2016
Research and Development, Sales and Marketing FDA, India, WHO, World Health Organisation, semler, semler research

The US Food and Drug Administration and the World Health Organisation have raised serious concerns related to violations of good …

News
stocks1

Weekly Movers: PTC Therapeutics, Celator Pharmaceuticals, Chiasma, Sarepta and more…

April 25, 2016
Research and Development, Sales and Marketing

With the earnings season in full swing this week investors focussed on the impact on stock moves as companies declared …

Feature

Pfizer, GSK’s anti-smoking drugs not linked to increase in serious neuropsychiatric adverse events – Study

April 25, 2016
Research and Development, Sales and Marketing

Pharma giant Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline) did not show an increase in serious neuropsychiatric adverse events …

News
stocks2

Valeant receives further default notices due to its delayed 10-K filing

April 25, 2016
Medical Communications, Sales and Marketing Valeant, default, risk, trouble, worry

Valeant Pharmaceuticals has issued a statement detailing that they have received additional notices of default under indentures due to its …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026